Top

Published in:

Open Access 01-12-2011 | Urinary Tract Infections (Jack D. Sobel, Section Editor)

Treatment Duration of Febrile Urinary Tract Infections

Authors: Willize E. van der Starre, Jaap T. van Dissel, Cees van Nieuwkoop

Published in: Current Infectious Disease Reports | Issue 6/2011

Abstract

Although febrile urinary tract infections (UTIs) are relatively common in adults, data on optimal treatment duration are limited. Randomized controlled trials specifically addressing the elderly and patients with comorbidities have not been performed. This review highlights current available evidence. Premenopausal, non-pregnant women without comorbidities can be treated with a 5–7 day regimen of fluoroquinolones in countries with low levels of fluoroquinolone resistance, or, if proven susceptible, with 14 days of trimethoprim-sulfamethoxazole. Oral β-lactams are less effective compared with fluoroquinolones and trimethoprim-sulfamethoxazole. In men with mild to moderate febrile UTI, a 2-week regimen of an oral fluoroquinolone is likely sufficient. Although data are limited, this possibly holds even in the elderly patients with comorbidities or bacteremia.

Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993;329:1328–34.PubMedCrossRef

Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents. 1999;11:189–96.PubMedCrossRef

Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–7.PubMedCrossRef

•• Gupta K, Hooton TM, Naber KG, et al.: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120. This recently updated guideline gives an overview of treatment recommendations in premenopausal, otherwise healthy women with febrile UTI. PubMedCrossRef

Kunin CM. Definition of acute pyelonephritis vs the urosepsis syndrome. Arch Intern Med. 2003;163:2393–4.PubMedCrossRef

Rubenstein JN, Schaeffer AJ. Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am. 2003;17:333–51.PubMedCrossRef

Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005;71:933–42.PubMed

Nicolle LE. Short-term therapy for urinary tract infection: success and failure. Int J Antimicrob Agents. 2008;31:40–5.CrossRef

ACOG Practice Bulletin No. 91. Treatment of urinary tract infections in nonpregnant women. Obstet Gynecol. 2008;111:785–94.CrossRef

10.

• European Association of Urology: guidelines on urological infections. Available at www.uroweb.org. Accessed 15-4-2011. This guideline outlines concisely and to-the-point the current recommendations for treatment of febrile UTI.

11.

Patel NS. Fluoroquinolone use is the predominant risk factor for the development of a new strain of clostridium difficile-associated disease. BJU Int. 2007;99:1333–4.PubMedCrossRef

12.

Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 2006;166:2518–24.PubMedCrossRef

13.

Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9.PubMedCrossRef

14.

Foxman B, Ki M, Brown P. Antibiotic resistance and pyelonephritis. Clin Infect Dis. 2007;45:281–3.PubMedCrossRef

15.

Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med. 1987;106:341–5.PubMed

16.

Cunha BA. Nitrofurantoin: an update. Obstet Gynecol Surv. 1989;44:399–406.PubMedCrossRef

17.

Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000;283:1583–90.PubMedCrossRef

18.

Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007;23:2637–45.PubMedCrossRef

19.

Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71:17–22.PubMedCrossRef

20.

Cronberg S, Banke S, Bergman B, et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis. 2001;33:339–43.PubMedCrossRef

21.

Richard GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology. 1998;52:51–5.PubMedCrossRef

22.

Arslan H, Azap OK, Ergonul O, et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56:914–8.PubMedCrossRef

23.

Chaniotaki S, Giakouppi P, Tzouvelekis LS, et al. Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece. Clin Microbiol Infect. 2004;10:75–8.PubMedCrossRef

24.

Sandberg T, Englund G, Lincoln K, et al. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 1990;9:317–23.PubMedCrossRef

25.

Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005;293:949–55.PubMedCrossRef

26.

van Haaren KAM, Visser HS, van Vliet S, et al. NHG-Standaard Urineweginfecties: tweede herziening [Guideline of the Dutch College of General Practitioners on urinary tract infections: second revision]. Huisarts Wet. 2005;48:341–52.CrossRef

27.

van Nieuwkoop C, Van’t Wout JW, Assendelft WJ, et al. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC Infect Dis. 2009;9:131.PubMedCrossRef

28.

Vorland LH, Carlson K, Aalen O. An epidemiological survey of urinary tract infections among outpatients in Northern Norway. Scand J Infect Dis. 1985;17:277–83.PubMed

29.

Ulleryd P, Zackrisson B, Aus G, et al. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int. 1999;84:470–4.PubMedCrossRef

30.

Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr Infect Dis Rep. 2005;7:9–16.PubMedCrossRef

31.

Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? Am J Med. 1999;106:327–34.PubMedCrossRef

32.

Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35:34–9.PubMedCrossRef

33.

Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med. 1999;159:53–8.PubMedCrossRef

34.

• van Nieuwkoop C, Van't Wout JW, Spelt IC, et al.: Prospective cohort study of acute pyelonephritis in adults: Safety of triage towards home based oral antimicrobial treatment. J Infect 2010;60:114–21. This observational study showed that a 2-week regimen of an oral fluoroquinolone might be sufficient, even in the elderly and patients with comorbidities. PubMedCrossRef

35.

Nicolle LE. Urinary tract infection in the elderly. J Antimicrob Chemother. 1994;33(Suppl A):99–109.PubMed

36.

Fang GD, Brennen C, Wagener M, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother. 1991;35:1849–55.PubMed

Title: Treatment Duration of Febrile Urinary Tract Infections
Authors: Willize E. van der Starre
Jaap T. van Dissel
Cees van Nieuwkoop
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 6/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-011-0211-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients

Herpes Simplex Virus Genital Infections: Current Concepts

Refractory Trichomoniasis in HIV-positive and HIV-negative Subjects

Recurrent Urinary Tract Infections in Kidney Transplant Recipients

Long-Term Voriconazole and Skin Cancer: Is There Cause for Concern?

Biopsy Procedures for Molecular Tissue Diagnosis of Invasive Fungal Infections

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials